Safex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -12.85%
- Profit Growth -11.39%
- Ebitda -24.22%
- Net Worth 3.50%
- Total Assets -4.13%
About Safex Pharmaceuticals
Safex Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 May 2013 and has a history of 11 years and nine months. Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Santosh Tiwari and Soni Tiwari serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999BR2013PTC020242
- Company No.
020242
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
What products or services does Safex Pharmaceuticals Private Limited offer?
Safex Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Allopathic Cough Syrup, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Sexual Wellness Products, Contraceptives, Dietary Supplements, Respiratory System Drugs, Anti Asthma Drug, Digestive System Drugs & Medicines.
Who are the key members and board of directors at Safex Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Tiwari  | Director | 04-May-2013 | Current |
| Soni Tiwari | Director | 04-May-2013 | Current |
Financial Performance of Safex Pharmaceuticals.
Safex Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 12.85% decrease. The company also saw a substantial fall in profitability, with a 11.39% decrease in profit. The company's net worth moved up by a moderate rise of 3.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Safex Pharmaceuticals?
In 2019, Safex Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Safex Pharmaceuticals?
Unlock and access historical data on people associated with Safex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Safex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Safex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.